Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you're interested in this service, you can try a free two-week trial today!
Puma Biotechnology (PBYI) has made its entire game up on the back of one drug, a "pan-HER" inhibitor called neratinib (branded Nerlynx). It offers a unique proposition from the more commonly used HER2 therapies marketed by Roche (